Dr. Shore encourages clinicians to implement hereditary cancer risk assessments in their practices

“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the takeaways of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.